Adalimumab and endoscopic dilatationin the treatment of inflammatory strictures due to Crohn'diseases: a case report of a treatment – naive patient.

Intestinal stenosis is one of the most common complications of Crohn’s disease with a prevalence of between 20% and 40% in the small intestine and between 7% and 15% in the colon [1]. Although endoscopic dilatation “throughthe- scope” (TTS) alone or in association with direct injection of steroids and surgery are the current treatments for strictures of the colon, endoscopic dilation represents the initial therapeutic approach for ileo-caecal and ileal strictures and is usually effective for short stenoses [2]. There is currently considerable doubt about the mid- to long-term efficacy of the combination of endoscopic dilatation and direct injection of infliximab [3,4]. We report here our experience of combination therapy with a biological agent, adalimumab, and endoscopic dilatation in a patient with inflammatory strictures of the ileo-caecal valve and ascending colon who had not previously received treatment with a biological agent.